|11 February 2016|

Global biotechnology giant Biogen has joined a leading public-private collaboration which drives a culture of pioneering drug development within the industry.

The Centre for Therapeutic Target Validation (CTTV) in the UK strives to improve the success rate for discovering new medicines. Originally formed by GSK, the Wellcome Trust Sanger Institute and the European Bioinformatics Institute (EMBL-EBI), the CTTV fosters strong working relationships between industry and academia for the purpose of developing open, transformative approaches to selecting and validating novel targets in drug development.

“We are committed to advancing evidence-based target discovery and opening up the field for researchers to create innovative methods and tools to accelerate the development of new medicines,” says Sally John, vice president, Computational Biology & Genomics at Biogen. “Being part of the CTTV helps us realise this vision and provides a practical, harmonised way to share data with the scientific community.”

Philip Ma, vice president, Digital Health Technology & Data Sciences at Biogen, added: “The importance of accessing and managing searchable, structured data is critical to sharing knowledge on target validation. We look forward to combining our expertise in data sciences with the leading capabilities of GSK, the Sanger Institute and EMBL-EBI.”